PMID- 19402889
OWN - NLM
STAT- MEDLINE
DCOM- 20090918
LR  - 20211020
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 9
DP  - 2009 Apr 29
TI  - Eligibility of patients with advanced non-small cell lung cancer for phase III 
      chemotherapy trials.
PG  - 130
LID - 10.1186/1471-2407-9-130 [doi]
AB  - BACKGROUND: Evidence that chemotherapy improves survival and quality of life in 
      patients with stage IIIB & IV non small cell lung cancer (NSCLC) is based on 
      large randomized controlled trials. The purpose of this study was to determine 
      eligibility of patients with advanced NSCLC for major chemotherapy trials. 
      METHODS: Physicians treating stage IIIB/IV NSCLC at Sydney Cancer Centre assessed 
      patient eligibility for the E1594, SWOG9509 and TAX326 trials for patients 
      presenting from October 2001 to December 2002. A review of the centre's registry 
      was used to obtain missing data. RESULTS: 199 patients with advanced NSCLC were 
      registered during the 14-month period. Characteristics of 100 patients were 
      defined prospectively, 85 retrospectively: 77% males, median age 68 (range 
      32-88), 64% stage IV disease. Only 35% met trial eligibility for E1594 and 28% 
      for SWOG9509 and TAX326. Common reasons for ineligibility were: co-morbidities 
      75(40%); ECOG Performance Status >or=2 72(39%); symptomatic brain metastasis 
      15(8%); and previous cancers 21(11%). Many patients were ineligible by more than 
      one criterion. CONCLUSION: The majority of patients with advanced NSCLC were 
      ineligible for the large chemotherapy trials. The applicability of trial results 
      to advanced lung cancer populations may be limited. Future trials should be 
      conducted in a more representative population.
FAU - Vardy, Janette
AU  - Vardy J
AD  - Sydney Cancer Centre, Concord Repatriation General Hospital and Royal Prince 
      Alfred Hospital, Sydney, NSW, Australia. jvardy@med.usyd.edu.au
FAU - Dadasovich, Ryan
AU  - Dadasovich R
FAU - Beale, Philip
AU  - Beale P
FAU - Boyer, Michael
AU  - Boyer M
FAU - Clarke, Stephen J
AU  - Clarke SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090429
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Clinical Trials, Phase III as Topic
MH  - Eligibility Determination/*standards/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Patient Selection
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Registries/statistics & numerical data
MH  - Retrospective Studies
MH  - Surveys and Questionnaires
PMC - PMC2683856
EDAT- 2009/05/01 09:00
MHDA- 2009/09/19 06:00
PMCR- 2009/04/29
CRDT- 2009/05/01 09:00
PHST- 2008/12/05 00:00 [received]
PHST- 2009/04/29 00:00 [accepted]
PHST- 2009/05/01 09:00 [entrez]
PHST- 2009/05/01 09:00 [pubmed]
PHST- 2009/09/19 06:00 [medline]
PHST- 2009/04/29 00:00 [pmc-release]
AID - 1471-2407-9-130 [pii]
AID - 10.1186/1471-2407-9-130 [doi]
PST - epublish
SO  - BMC Cancer. 2009 Apr 29;9:130. doi: 10.1186/1471-2407-9-130.